ImageneBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ImageneBio is a private, clinical-stage biotech focused on developing a potential best-in-class anti-OX40 monoclonal antibody, IMG-007, for immunological and inflammatory diseases. The company is led by an experienced management team with a track record in drug development and is backed by notable venture capital investors from its board. With a single, differentiated asset in clinical development, the company's near-term value is heavily tied to the success of IMG-007 in treating conditions like alopecia areata and other undisclosed indications.

Immunological DiseasesAutoimmune DiseasesInflammatory DiseasesAlopecia Areata

Technology Platform

Monoclonal antibody engineering focused on the OX40/OX40L pathway, featuring extended half-life and a non-depleting mechanism of action.

Opportunities

The large and growing market for autoimmune diseases, particularly in validated areas like Alopecia Areata, presents a significant opportunity.

IMG-007's differentiated profile (non-depleting, extended half-life) could address unmet needs for safer, more convenient therapies, allowing it to capture market share if clinical efficacy is proven.

Risk Factors

The company faces high clinical development risk as its value is concentrated in a single asset, IMG-007.

It also operates in a competitive OX40 inhibitor landscape and is dependent on raising additional capital to fund operations through costly clinical trials.

Competitive Landscape

The OX40/OX40L pathway is a competitive target, with several large pharmaceutical and biotechnology companies developing antibodies. ImageneBio competes by emphasizing IMG-007's non-depleting mechanism and extended half-life, aiming for a best-in-class safety and convenience profile.

More companies in Biologics / Biosimilars →More companies in United States →